Tempus AI (NASDAQ:TEM) Stock: Insider Eric Lefkofsky Sells 17,074 Shares

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Eric Lefkofsky sold 17,074 shares of the business’s stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total transaction of $1,076,003.48. Following the transaction, the chief executive officer directly owned 2,081,056 shares in the company, valued at approximately $131,148,149.12. The trade was a 0.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

Tempus AI stock opened at $53.98 on Friday. The company has a market capitalization of $9.85 billion, a price-to-earnings ratio of -50.92 and a beta of 3.61. The company has a debt-to-equity ratio of 2.70, a quick ratio of 2.48 and a current ratio of 2.61. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $89.09. The company’s 50 day simple moving average is $72.79 and its 200-day simple moving average is $57.55.

Tempus AI (NASDAQ:TEM – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The firm had revenue of $411.54 million during the quarter, compared to analysts’ expectations of $409.39 million. During the same period in the previous year, the firm posted ($0.46) EPS. Tempus AI’s revenue for the quarter was up 23.1% on a year-over-year basis. As a group, equities research analysts expect that Tempus AI, Inc. will post -1.20 earnings per share for the current year.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently bought and sold shares of the business. PCM Encore LLC acquired a new stake in shares of Tempus AI in the 3rd quarter valued at about $201,000. Advisors Asset Management Inc. bought a new stake in shares of Tempus AI during the 3rd quarter valued at about $3,977,000. Integrated Wealth Concepts LLC raised its stake in Tempus AI by 44.3% during the third quarter. Integrated Wealth Concepts LLC now owns 3,618 shares of the company’s stock worth $296,000 after acquiring an additional 1,110 shares during the period. Schwarz Investment Partners Inc. acquired a new position in Tempus AI in the third quarter valued at approximately $109,000. Finally, New York State Common Retirement Fund raised its position in shares of Tempus AI by 3.0% during the 3rd quarter. New York State Common Retirement Fund now owns 54,400 shares of the company’s stock worth $4,455,000 after purchasing an additional 1,600 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

TEM has been the subject of several analyst reports. Jefferies Financial Group upgraded Tempus AI from an “underperform” rating to a “hold” rating and upped their price target for the stock from $35.00 to $70.00 in a research note on Tuesday, November 3rd. Guggenheim upped their target price on Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Canaccord Genuity Group increased their price objective on shares of Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Roth Capital assumed coverage on shares of Tempus AI in a research note on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $85.00 price target on shares of Tempus AI in a report on Thursday. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $79.37.

Get Our Latest Stock Report on TEM

Tempus AI News Summary

Investors following TEM have been watching these news items:

  • Positive Sentiment: Tempus plans to present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium, which could increase visibility for its research and precision-medicine platform. Tempus to present 16 abstracts
  • Positive Sentiment: The company extended its strategic collaboration with AstraZeneca. Separate investor coverage cited data agreements expected to generate $193 million over five years and oncology pricing changes expected to add $80 million in average selling price during 2027, supporting the longer-term growth case. AstraZeneca collaboration Investor takeaways
  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating confidence in Tempus’s outlook. HC Wainwright rating

About Tempus AI

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Featured Stories

Insider Buying and Selling by Quarter for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.